Pruritus News and Research

RSS
Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis

COVID-19 vaccine can elicit a distinct T cell-dominant immune-mediated hepatitis

FDA approves an intravenous medication to treat patients with Pompe disease

FDA approves an intravenous medication to treat patients with Pompe disease

Next-Generation Sequencing and the Diagnosis of Disease

Next-Generation Sequencing and the Diagnosis of Disease

FDA approves Stratagraft for thermal burn treatment in adult patients

FDA approves Stratagraft for thermal burn treatment in adult patients

FDA issues EUA for bamlanivimab and etesevimab for COVID-19 treatment

FDA issues EUA for bamlanivimab and etesevimab for COVID-19 treatment

Symptom under-recognition may be common in breast cancer patients treated with radiotherapy

Symptom under-recognition may be common in breast cancer patients treated with radiotherapy

Mallinckrodt publishes results of StrataGraft regenerative tissue Phase 1b study

Mallinckrodt publishes results of StrataGraft regenerative tissue Phase 1b study

Racial and ethnic disparities exist in palliative care use among hospitalized patients with ESKD

Racial and ethnic disparities exist in palliative care use among hospitalized patients with ESKD

Study explains why some drugs work well in ameliorating side effects of chemotherapy

Study explains why some drugs work well in ameliorating side effects of chemotherapy

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1

Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Pediatric antibiotic prescriptions lead to nearly 70,000 ER visits in the U.S. each year

Pediatric antibiotic prescriptions lead to nearly 70,000 ER visits in the U.S. each year